SEER stats for breast cancer [Internet]. [cited 2021 Jul 25]. Available from: Available at https://seer.cancer.gov
Wojtyla, C., Bertuccio, P., Wojtyla, A. & La Vecchia, C. European patterns in breast cancer death, 1980–2017 and forecasts to 2025. Eur. J. Cancer 152, 4–17 (2021).
Pérez-García, J., Gebhart, G., Ruiz Borrego, M., Stradella, A., Bermejo, B. P. S. et al. Chemotherapy de-escalation utilizing an 18F-FDG-PET-based pathological response-adapted method in clients with HER2-positive early breast cancer (PHERGain): A multicentre, randomised, open-label, non-comparative, stage 2 trial. Lancet Oncol. 22 (2021).
Blumen, H., Fitch, K. & Polkus, V. Comparison of treatment expenses for breast cancer, by growth phase and kind of service. Am. Health Drug Benefits 9, 23–32 (2016).
Varsanik, M. A. & Shubeck, S. P. De-intensifying breast cancer treatment. Surg. Clin. N. Am. 103, 83–92 (2023).
De Abreu, F. B., Schwartz, G. N., Wells, W. A. & Tsongalis, G. J. Personalized treatment for breast cancer. Clin. Genet. 86, 62–67 (2014).
ESMO. Personalised Medicine at a Glance: Breast Cancer [Internet]. [cited 2022 Nov 28]. Available from: https://www.esmo.org/for-patients/personalised-medicine-explained/breast-cancer
ASCO 2021 Delivers Personalized Treatment Approaches Across Breast Cancer [Internet]. OncLive. [cited 2022 Nov 28]. Available from: https://www.onclive.com/view/asco-2021-delivers-personalized-treatment-approaches-across-breast-cancer
Yankeelov, T. E. et al. Multi-scale modeling in medical oncology: Opportunities and barriers to success. Ann. Biomed. Eng. 44, 2626–2641 (2016).
Franssen, L. C., Lorenzi, T., Burgess, A. E. F. & Chaplain, M. A. J. A mathematical structure for designing the metastatic spread of cancer. Bull. Math. Biol. 81, 1965–2010 (2019).
Kirkwood, T. B. L. Deciphering death: A commentary on Gompertz (1825) “On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies”. Philos. Trans. R. Soc. Lond. B Biol. Sci. 370, 20140379 (2015).
Norton, L. A Gompertzian design of human breast cancer development. Cancer Res. 48, 7067–7071 (1988).
Barbolosi, D., Ciccolini, J., Lacarelle, B., Barlési, F. & André, N. Computational oncology–mathematical modelling of drug routines for accuracy medication. Nat. Rev. Clin. Oncol. 13, 242–254 (2016).
Deisboeck, T. S., Zhang, L., Yoon, J. & Costa, J. In silico cancer modeling: Is it all set for primetime? Nat. Clin. Pract. Oncol. 6, 34–42 (2009).
Weis, J. A. et al. Predicting the reaction of breast cancer to neoadjuvant treatment utilizing a mechanically paired reaction-diffusion design. Cancer Res. 75, 4697–4707 (2015).
Jarrett, A. M. et al. Mathematical designs of growth cell expansion: An evaluation of the literature. Expert Rev. Anticancer Ther. 18, 1271–1286 (2018).
Marino, G. et al. Towards a decisional support group in breast cancer surgical treatment based upon mass transfer modeling. Int. Commun. Heat Mass Transf. 129, 105733 (2021).
Schettini, F. et al. Clinical, radiometabolic and immunologic results of olaparib in Locally Advanced Triple Negative Breast cancer: The OLTRE window of chance trial. Front. Oncol. 11, 2496 (2021).
Eisenhauer, E. A. et al. New reaction examination requirements in strong tumours: Revised RECIST standard (variation 1.1). Eur. J. Cancer 45, 228–47 (2009).
Ruocco, G. Introduction to Transport Phenomena Modeling A Multiphysics, General Equation-Based Approach [Internet]. First edn. Vol. 2018 (Springer Publishing Company, 2018). Available from: http://lib.ugent.be/catalog/ebk01:4100000002485311
Gallicchio, R. et al. A mass transfer design for computational forecast of expansion and treatment result of non-Hodgkin lymphoma. Int. Commun. Heat Mass Transf. 125, 105332 (2021).
Castorina, P. & Carco’, D. Nutrient supply, cell spatial connection and Gompertzian tumor development. Theory Biosci. 140, 197–203 (2021).
Petretta, M., Storto, G., Pellegrino, T., Bonaduce, D. & Cuocolo, A. Quantitative evaluation of myocardial blood circulation with SPECT. Prog. Cardiovasc. Dis. 57, 607–614 (2015).
Erdogan, B. & Webb, D. J. Cancer-associated fibroblasts regulate development aspect signaling and extracellular matrix redesigning to control growth transition. Biochem. Soc. Trans. 45, 229–236 (2017).
Weis, J. A., Miga, M. I. & Yankeelov, T. E. Three-dimensional image-based mechanical modeling for forecasting the reaction of breast cancer to neoadjuvant treatment. Comput. Methods Appl. Mech. Eng. 314, 494–512 (2017).
Tang, L. et al. Computational modeling of 3D tumor development and angiogenesis for chemotherapy examination. PLoS ONE 9, e83962 (2014).
Bundred, N. et al. Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: A stage I multicentre trial in clients scheduled for optional breast cancer surgical treatment. Investig. New Drugs 31, 949–958 (2013).
EMA. Lynparza [Internet]. European Medicines Agency (2018) [cited 2022 Dec 5]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza
COMSOL® Software Version 5.6 Release Highlights [Internet]. COMSOL. [cited 2022 Nov 29]. Available from: https://www.comsol.com/release/5.6
Loi, S. et al. Tumor-penetrating lymphocytes and diagnosis: A pooled private client analysis of early-stage triple-negative breast cancers. J. Clin. Oncol. 37, 559–569 (2019).
Dieci, M. V. et al. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, consisting of suggestions to examine TILs in recurring illness after neoadjuvant treatment and in cancer in situ: A report of the worldwide immuno-oncology biomarker working group on breast cancer. Semin. Cancer Biol. 52, 16–25 (2018).
Park, J. H. et al. Prognostic worth of tumor-infiltrating lymphocytes in clients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. Ann. Oncol. 30, 1941–1949 (2019).
Yang, H.-T., Shah, R. H., Tegay, D. & Onel, K. Precision oncology: Lessons found out and obstacles for the future. Cancer Manag. Res. 11, 7525–7536 (2019).
Schwartzberg, L., Kim, E. S., Liu, D. & Schrag, D. Precision oncology: Who, how, what, when, and when not? Am. Soc. Clin. Oncol. Educ. Book 37, 160–169 (2017).
Burstein, H. J. et al. Customizing regional and systemic treatments for females with early breast cancer: The St. Gallen worldwide agreement standards for treatment of early breast cancer 2021. Ann. Oncol. 32, 1216–35 (2021).
Cardoso, F. et al. Early breast cancer: ESMO medical practice standards for medical diagnosis, treatment and follow-up†. Ann. Oncol. 30, 1194–1220 (2019).
Schettini, F. et al. Multiple Bayesian network meta-analyses to develop healing algorithms for metastatic triple negative breast cancer. Cancer Treat. Rev. 111, 102468 (2022).
Schettini, F. et al. Poly (ADP-ribose) polymerase inhibitors in strong tumours: Systematic evaluation and meta-analysis. Eur. J. Cancer 149, 134–152 (2021).
Tutt, A. N. J. et al. Adjuvant olaparib for clients with BRCA1- or BRCA2-mutated breast cancer. N. Engl. J. Med. 384, 2394–2405 (2021).
Current Challenges in Oncology | proventainternational.com [Internet]. Proventa International (2021) [cited 2022 Dec 7]. Available from: https://proventainternational.com/biomarker-discovery-and-validation-current-challenges-in-oncology/
Hey, S. P. et al. Challenges and opportunities for biomarker recognition. J. Law Med. Ethics 47, 357–361 (2019).
Ptolemy, A. S. & Rifai, N. What is a biomarker? Research financial investments and absence of medical combination require an evaluation of biomarker terms and recognition schema. Scand. J. Clin. Lab. Investig. Suppl. 242, 6–14 (2010).
Davey, M. G., Hynes, S. O., Kerin, M. J., Miller, N. & Lowery, A. J. Ki-67 as a prognostic biomarker in intrusive breast cancer. Cancers (Basel) 13, 4455 (2021).
Schettini, F., Brasó-Maristany, F., Kuderer, N. M. & Prat, A. A point of view on the advancement and absence of interchangeability of the breast cancer intrinsic subtypes. NPJ. Breast Cancer 8, 85 (2022).
Aleskandarany, M. A. et al. Prognostic worth of expansion assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Res. 14, R3 (2012).
Salgado, R. et al. The examination of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by a worldwide TILs working group 2014. Ann. Oncol. 26, 259–271 (2015).
Dieci, M. V. et al. Prognostic worth of tumor-infiltrating lymphocytes on recurring illness after main chemotherapy for triple-negative breast cancer: A retrospective multicenter research study. Ann. Oncol. 25, 611–618 (2014).
de Jong, V. M. T. et al. Prognostic worth of stromal tumor-infiltrating lymphocytes in young, node-negative, triple-negative breast cancer clients who did not receive (neo)adjuvant systemic treatment. J. Clin. Oncol. 40, 2361–2374 (2022).
Litton, J. K. et al. Neoadjuvant talazoparib for clients with operable breast cancer with a germline BRCA pathogenic version. J. Clin. Oncol. 38, 388–394 (2020).
Spring, L. M. et al. Neoadjuvant research study of niraparib in clients with HER2-negative, BRCA-mutated, resectable breast cancer. Nat. Cancer 3, 927–931 (2022).
Cortes, J., Pérez-García, J., Ruiz-Borrego, M., Stradella, A., Bermejo, B., Escrivá-de-Romaní, S. et al. 3-year intrusive disease-free survival (iDFS) of the strategy-based, randomized stage II PHERGain trial assessing chemotherapy (CT) de-escalation in human skin development aspect receptor 2-positive (HER2[+]) early breast cancer (EBC). J. Clin. Oncol. 41 (suppl 17; abstr LBA506) (2023).
